The company has a market capitalization of $22.66 billion and a price-to-earnings ratio of 45.56. On year trading price range hit the peak level of $112.00 and touched the lowest level of $62.53 and its distance from 52 week high is -5.04% and current price is above +70.08% from 52 week low.
Advertisement
Edwards Lifesciences Corp. (NYSE:EW) last announced its quarterly earnings data on Tuesday, July 26th.
Excluding one-time items, Edwards said second-quarter earnings rose to 76 cents a share from 57 cents in the year-ago period.
For the quarter, sales increased 23.1 percent compared with the same period a year ago to $759.3 million, including a 48.7 percent increase to $418.6 million in the transcatheter heart valve therapy division.
-Earnings (Q2): $164.6 Mln. vs. $125.7 Mln. past year.
If we have a peek on EPS and surprise factor history during last four quarters, for the previous quarter ended on 3/2016, the consensus mean EPS was $0.66 while the company reported $0.71 EPS on 4/26/2016 AMC with a difference of 0.05 marking a surprise factor of 7.58%.
Based on its first half results, Edwards said it expects full-year sales to be at the high end of the $2.7 billion to $3.0 billion range it previously reported. Edwards Lifesciences Corp are listed in the Health Care sector within NYSE. Oakworth Capital Inc. bought a new position in Edwards Lifesciences Corp. during the second quarter worth about $126,000. BTIG Research upgraded Edwards Lifesciences Corp. from a “neutral” rating to a “buy” rating and set a $115.00 target price on the stock in a report on Saturday, April 2nd. Checchi Capital Advisers LLC raised its position in Edwards Lifesciences Corp.by 3.9% in the second quarter. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $110.00 price target (up from $98.00) on shares of Edwards Lifesciences Corp.in a report on Monday, April 4th.
Leerink also revised up its target price on EW stock from $125 to $130, and set an Outperform rating. Further, the bottom line results also surpassed Edwards Lifesciences’ guidance of 67-73 cents.
Royal Bank of Canada reduced its position in shares of Edwards Lifesciences Corp.
Canaccord raised its price objective on EW shares from $132 to $140, and maintained its Buy rating.
Advertisement
In other Edwards Lifesciences Corp. news, Director Steven R. Loranger acquired 5,000 shares of the stock in a transaction that occurred on Tuesday, May 24th. The Hedge Fund company now holds 6,600 shares of EW which is valued at $704,286. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The shares were sold at an average price of $98.44, for a total value of $1,343,706.00. The disclosure for this sale can be found here. Overall, we remain committed to aggressively investing in structural heart disease and critical care technologies. It is a manufacturer of heart valve systems and fix products used to replace or fix a patient’s diseased or defective heart valve.
